{"product_id":"tevapharm-marketing-mix","title":"Teva Pharmaceutical Industries Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eTeva’s product portfolio blends branded specialty drugs and generics, balanced by cost-competitive pricing, global distribution networks, and targeted promotional tactics that prioritize healthcare professionals and payers; this snapshot only hints at the strategy. Get the full 4P’s Marketing Mix Analysis—editable, data-driven, and presentation-ready—to uncover pricing architecture, channel performance, promo ROI, and actionable recommendations for business or academic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Generics Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva is the global leader in generics, holding roughly 10% of the global generics market and offering medicines across nearly every therapeutic area; its 2024 generics revenue was about $8.1B. By end-2025 Teva shifted toward complex generics—injectables, inhalation, biosimilar-delivery—which now account for ~35% of its portfolio and carry 3–5pp higher gross margins. This scale keeps Teva a key partner for payers cutting costs while preserving care quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovative Specialty Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpteva has pivoted toward specialty medicines in neurology oncology and immunology with sales rising to about billion roughly of total revenue.\u003e\n\u003cpaustedo disorders and ajovy prevention drive growth via new indications improved delivery austedo net sales were million in million.\u003e\n\u003cpthis specialty focus offsets low-margin generics of sales by adding patent-protected higher-margin products addressing large unmet needs.\u003e\n\u003c\/pthis\u003e\u003c\/paustedo\u003e\u003c\/pteva\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilars Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva has pushed biosimilars to capture biologic patent expiries through 2025, targeting a global market forecasted at $75–85 billion by 2025; Teva aimed for several launches and partnerships to win ~3–5% share in key oncology and autoimmune segments.\u003c\/p\u003e\n\u003cp\u003eLower-cost biosimilars cut therapy costs 20–40%, giving payers cheaper chronic-disease options and supporting Teva’s margin recovery after generics pressure.\u003c\/p\u003e\n\u003cp\u003eThese products need complex biologics manufacturing and regulatory expertise, creating a high technical moat versus small generics and protecting Teva’s R\u0026amp;D and facility investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva combines tech with pharmacology via Digihaler inhalers and smart interfaces that turned devices into service platforms; Digihaler logged \u0026gt;1M patient uses by 2024 and cut missed doses by ~25% in trials, boosting adherence-driven repeat sales.\u003c\/p\u003e\n\u003cp\u003eReal-time adherence and respiratory metrics feed providers and patients, enabling data-driven care and potential Rx optimization; Teva reports digital solutions contributed to a small but growing share of specialty revenues in 2024 (~2‑3%).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDigihaler: \u0026gt;1M uses by 2024\u003c\/li\u003e\n\u003cli\u003eAdherence improvement: ~25% in studies\u003c\/li\u003e\n\u003cli\u003eRevenue impact: ~2–3% of specialty sales (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOver-the-Counter (OTC) Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTeva’s OTC portfolio complements prescription revenues with consumer health products that generated about $1.1 billion in 2024, stabilizing cash flow across markets and boosting direct brand recognition.\u003c\/p\u003e\n\u003cp\u003eThe company emphasizes legacy OTC brands for cough, pain, and allergy relief, leveraging established trust to drive repeat purchase without physician visits; OTC margins are typically higher and less volatile than generics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 OTC sales ≈ $1.1B\u003c\/li\u003e\n\u003cli\u003eKey categories: analgesics, cough\/cold, allergy\u003c\/li\u003e\n\u003cli\u003eHigher gross margins vs generics\u003c\/li\u003e\n\u003cli\u003eGlobal reach strengthens brand equity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva: Generics powerhouse—$8.1B revenue, 35% complex generics, growing specialty \u0026amp; OTC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva: global generics leader (~10% market share), 2024 generics revenue $8.1B; specialty sales $3.1B (2024) with Austedo $650M, Ajovy $420M; complex generics ~35% portfolio by end‑2025, +3–5pp gross margin; biosimilars target 3–5% market share in oncology\/autoimmune; OTC sales $1.1B (2024); Digihaler \u0026gt;1M uses, ~25% adherence lift.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics rev\u003c\/td\u003e\n\u003ctd\u003e$8.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty rev\u003c\/td\u003e\n\u003ctd\u003e$3.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAustedo\u003c\/td\u003e\n\u003ctd\u003e$650M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAjovy\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC rev\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigihaler uses\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComplex generics share\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a company-specific deep dive into Teva Pharmaceutical Industries’ Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground the analysis for managers, consultants, and marketers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Teva’s 4Ps into a concise snapshot highlighting product portfolio strength, pricing strategies for generics and specialty drugs, targeted promotion tactics, and global distribution channels—designed for quick leadership review and rapid strategic alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Pharmacy Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTeva runs a direct-to-pharmacy network that supplies 30,000+ pharmacies globally, cutting reliance on wholesalers in key markets and improving gross margins by ~120 basis points in 2024.\u003c\/p\u003e\n\u003cp\u003eVertical integration lets Teva retain more margin on high-demand generics like AVODART equivalents, while lowering fulfillment lead times from 5 days to under 48 hours in major regions.\u003c\/p\u003e\n\u003cp\u003eBy 2025 Teva deployed AI inventory forecasting, reducing stockouts by 40% and trimming working capital tied to inventory by an estimated $200–$300 million annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Hospital Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA significant share of Teva Pharmaceutical Industries' specialty and biosimilar volume—about 35% of its global specialty sales in 2024—moves through institutional tenders and hospital systems, so Teva keeps dedicated tender teams to secure large-scale contracts and lists its products as preferred inpatient choices; this placement is critical for adoption of complex injectables and oncology treatments that need clinical supervision, and hospital channel wins supported roughly $1.2 billion in 2024 revenues for Teva's specialty portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva operates dozens of sites globally, producing near key markets to cut stockouts; as of 2025 it reports ~40 manufacturing sites with 6 high-efficiency mega-plants handling 60% of API and finished-dose volumes.\u003c\/p\u003e\n\u003cp\u003eGeographic spread reduces supply-chain risk amid geopolitical tension and local regulatory shifts; Teva says regional sourcing lowered disruption days by 45% in 2024 versus 2019.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline Pharmacy Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTeva partners with major e-pharmacies and mail-order services so telehealth patients can access its generics and specialty brands seamlessly, supporting online fulfillment that grew 28% in pharma prescriptions in 2024 (IQVIA).\u003c\/p\u003e\n\u003cp\u003eDigital placement protects Teva’s market share as home delivery and virtual consultations rise; in 2024 mail-order channels accounted for ~15% of U.S. prescription volume for generics (CMS).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartnerships with top e-pharmacies and mail-order\u003c\/li\u003e\n\u003cli\u003eSupports telehealth-to-delivery patient journeys\u003c\/li\u003e\n\u003cli\u003eBacked by 28% online Rx growth (2024, IQVIA)\u003c\/li\u003e\n\u003cli\u003eMail-order ~15% of U.S. generic Rx volume (2024, CMS)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpteva expanded in asia-pacific and latin america where generics sales grew accounted for roughly of group revenue helping offset margin pressure western markets.\u003e\n\u003cpby adapting distribution partnerships smaller pack sizes and patient-assistance programs lowered unit cost reached rising middle classes asia-pacific prescription volumes rose yoy in\u003e\n\u003cpgeographic diversification reduced exposure to us pricing cuts: international sales provided of total revenue in stabilizing cash flow.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e22% of revenue from high-growth regions (2024)\u003c\/li\u003e\n\u003cli\u003eAsia-Pacific Rx volume +9% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eInternational sales ~38% of revenue (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pgeographic\u003e\u003c\/pby\u003e\u003c\/pteva\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTeva: 30k+ pharmacies, 40 sites, AI cuts stockouts 40%—online Rx +28%, Intl 38%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTeva’s place strategy blends a 30,000+ direct-pharmacy network, ~40 global sites (6 mega-plants), 35% specialty hospital share, AI forecasting cutting stockouts 40%, and digital\/mail-order channels (online Rx +28% in 2024; mail-order ~15% US generics), with international sales ~38% of revenue (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect pharmacies\u003c\/td\u003e\n\u003ctd\u003e30,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing sites\u003c\/td\u003e\n\u003ctd\u003e~40 (6 mega)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty hospital share\u003c\/td\u003e\n\u003ctd\u003e35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockout reduction\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline Rx growth\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl rev share\u003c\/td\u003e\n\u003ctd\u003e~38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eTeva Pharmaceutical Industries 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Teva Pharmaceutical Industries 4P's Marketing Mix analysis you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eIt covers Product, Price, Place and Promotion with actionable insights and is the exact, fully complete document ready for immediate use.\u003c\/p\u003e\n\u003cp\u003eYou’re viewing the same editable, high-quality file included in your order; download it right after checkout with full confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750284603769,"sku":"tevapharm-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/tevapharm-marketing-mix.png?v=1772223970","url":"https:\/\/growthsharematrix.com\/products\/tevapharm-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}